Bio-Techne's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $13 Mil. Bio-Techne's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $543 Mil. Bio-Techne's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $1,964 Mil.
Bio-Techne's debt to equity for the quarter that ended in Dec. 2023 was 0.28.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Bio-Techne's Debt-to-Equity or its related term are showing as below:
TECH'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02 Med: 0.27 Max: 0.51
Current: 0.28
During the past 13 years, the highest Debt-to-Equity Ratio of Bio-Techne was 0.51. The lowest was 0.02. And the median was 0.27.
Bio-Techne Debt-to-Equity Historical Data
The historical data trend for Bio-Techne's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
|
Bio-Techne Annual Data
|
|
Trend |
Jun14 |
Jun15 |
Jun16 |
Jun17 |
Jun18 |
Jun19 |
Jun20 |
Jun21 |
Jun22 |
Jun23 |
| Debt-to-Equity |
|
Get a 7-Day Free Trial
|
|
|
0.43 |
0.31 |
0.27 |
0.19 |
0.23 |
|
Bio-Techne Quarterly Data
|
|
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Debt-to-Equity |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
0.16 |
0.25 |
0.23 |
0.28 |
0.28 |
Competitive Comparison
For the Biotechnology subindustry, Bio-Techne's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio-Techne Debt-to-Equity Distribution
For the Biotechnology industry and Healthcare sector, Bio-Techne's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Bio-Techne's Debt-to-Equity falls into.
Bio-Techne Debt-to-Equity Calculation
Debt to Equity measures the financial leverage a company has.
Bio-Techne's Debt to Equity Ratio for the fiscal year that ended in Jun. 2023 is calculated as
Bio-Techne's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio-Techne (Bio-Techne) Business Description
Traded in Other Exchanges
Address
614 McKinley Place N.E., Minneapolis, MN, USA, 55413
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Executives
| Roeland Nusse |
director |
473 TENNESSEE, PALO ALTO CA 94306 |
| William Geist |
officer: PRESIDENT, PROTEIN SCIENCES |
900 MIDDLESEX TURNPIKE, C/O QUANTERIX CORPORATION, BILLERICA MA 01821 |
| Charles R. Kummeth |
director, officer: Chief Executive Officer |
425 MARTINGALE ROAD, SUITE 1000, SCHAUMBURG IL 60173-2213 |
| Shane Bohnen |
officer: SVP - General Counsel |
614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413 |
| Brenda S. Furlow |
officer: SVP - General Counsel |
614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413 |
| John L Higgins |
director |
11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037 |
| Robert V Baumgartner |
director |
5775 WAYZATA BOULEVARD, SUITE 400, MINNEAPOLIS MN 55416 |
| Kim Kelderman |
officer: Pres. Diagnostics & Genom |
614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413 |
| Norman David Eansor |
officer: SVP Biotech |
8100 SOUTHPARK WAY, A-8, LITTLETON CO 80120 |
| James Hippel |
officer: Chief Financial Officer |
614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413 |
| Joseph D Keegan |
director |
C/O MOLECULAR DEVICES CORP, 1311 ORLEANS DRIVE, SUNNYVALE CA 94089 |
| Alpna Seth |
director |
614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413 |
| Julie L Bushman |
director |
185 SOUTH 84TH STREET, SUITE 200, MILWAUKEE WI 53214 |
| Rupert Vessey |
director |
C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901 |
| Randolph C Steer |
director |
614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413 |
Bio-Techne (Bio-Techne) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TECH has been successfully added to your